The
global brachytherapy market size is expected to reach USD
452.3 million by 2025, according to a new report by Grand View Research,
Inc. It is projected to register a CAGR of 4.6% over the forecast period.
Technological advancements and R&D investments by key market players are
some of the major growth drivers. In August 2017, Salutaris Medical Devices
launched the trial of brachytherapy treatment for neovascular age-related
macular degeneration. The trial is to study surgeons’ ease in using SalutarisMD
system (SMD-DA system) along with the anti-VEGF treatment regimen and the
safety of the same.
According
to the International Agency for Research on Cancer, in 2015, more than 15
million people suffered from cancer while 8.8 million deaths were caused by the
disease worldwide. This number is expected to rise to 24 million by 2035. It is
also estimated that 23.6 million new cancer cases will be diagnosed by 2030.
According
to the American Brachytherapy Society, safety, and efficacy of brachytherapy
treatment over other cancer treatments, such as chemotherapy and surgery, is
expected to boost the market. In addition, favorable reimbursement guidelines
are expected to contribute to the rising adoption of brachytherapy.
The
Center for Medicare and Medicaid (CMS) implemented new High-Dose Rate (HDR)
treatment delivery codes in 2016. The final rates for 2017 included an increase
of approximately 5% to 6% in payments. Increasing usage of these technologies
and the presence of favorable reimbursement policies in developing countries
are expected to further fuel growth of the brachytherapy market.
Full Research Report On Brachytherapy Market Visit Here:
https://www.grandviewresearch.com/industry-analysis/brachytherapy-devices-market
Further key
findings from the study suggest:
- In 2017, HDR brachytherapy
held the largest market share in terms of revenue. The segment is also
expected to witness the fastest CAGR over the forecast period due to the
growing incidence of breast cancer, unhealthy lifestyle, rising R&D
investments, and the introduction of technologically improved treatment
solutions
- Application segment is
further divided into prostate cancer, breast cancer, gynecological cancer,
and other types of cancer. Breast cancer is expected to witness the
fastest CAGR over the forecast period
- North America held the
dominant market in terms of revenue in 2017. On the other hand, Asia
Pacific is expected to witness the fastest CAGR over the forecast period
- Eckert & Ziegler BEBIG;
iCAD, Inc.; IsoRay Medical, Inc.; Elekta AB; C.R. Bard, Inc.; CIVCO
Medical Solutions; etc. are some of the key players in the brachytherapy
market.
Request a Sample Copy of the Report @
https://www.grandviewresearch.com/industry-analysis/brachytherapy-devices-market/request/rs1
Grand View Research has segmented
the global brachytherapy market on the basis of type, application, and region:
Brachytherapy Type
Outlook (Revenue, USD Million, 2014 - 2025)
- High Dose Rate (HDR)
Brachytherapy
- Low Dose Rate (HDR)
Brachytherapy
Brachytherapy
Application Outlook (Revenue, USD Million, 2014 - 2025)
- Prostate Cancer
- Gynecological Cancer
- Breast Cancer
- Other Cancers
Brachytherapy
Regional Outlook (Revenue, USD Million, 2014 - 2025)
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- Asia Pacific
- Japan
- China
- Latin America
- Brazil
- Mexico
- Middle East & Africa
- South Africa
About Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
For more info visit @ https://www.grandviewresearch.com
No comments:
Post a Comment